KalVista shares sink after ending drug trial for hereditary disease
(Reuters) -KalVista Pharmaceuticals Inc said on Tuesday it has ended a mid-stage study for its drug to prevent recurrent swelling attacks in people with hereditary angioedema due to safety concerns,…